Antibiotic Concentrations After MassivE Transfusion Study
NCT06699901 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 417
Last updated 2025-02-11
Summary
Combat and civilian trauma frequently result in open wounds that are at risk for infection. Data from the Department of Defense Trauma Registry demonstrate that 74% of combat trauma casualties have an open wound. The Committee on Tactical Combat Casualty Care, the Prolonged Field Care Working Group, and the Joint Trauma System clinical practice guidelines recommend antibiotic prophylaxis for open wounds after trauma. The civilian setting has similar risks of open wound infection after trauma. In parallel, current practice guidelines recommend the aggressive use of balanced blood products during resuscitation. It remains unclear how the replacement of blood after hemorrhage through transfusion may affect antibiotic concentrations. Data is necessary to better understand this relationship to enhance wound prophylaxis antibiotic dosing, particularly in severely wounded casualties who receive blood products during massive transfusions. It remains unclear how these resuscitation methods may alter pharmacokinetics. The investigators hypothesize that drug concentrations decrease in direct relation to the amount of blood transfused during low-volume, massive, and supermassive transfusion after trauma compared to patients who receive no blood products. The investigators seek to understand the relationship between drug concentrations and blood product administration using a non-compartmentalized model in the setting of hemorrhage. Specifically, they will (1) obtain drug concentrations at regular intervals during the first 12-18 hours after administration of antibiotics, (2) determine how much blood products and fluids are transfused during the 12 hours prior to antibiotic and 24 hours post-administration, and (3) perform data modeling to understand the relationship between blood transfusions and drug concentrations to inform data-driven dosing models. Liquid chromatography methods will be developed to measure drug concentrations. The investigators will conduct a prospective, multicenter study at two large trauma centers - Brooke Army Medical Center and the University of Colorado Hospital. They will seek to enroll any participant who is hospitalized or anticipated hospital admission for acute trauma and receives an antibiotic on the study list during their index hospitalization. They will then model the drug levels against the amount of blood and fluid infused to create an understanding of the pharmacokinetics of antibiotic wound prophylaxis.
Conditions
- Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents
Interventions
- OTHER
-
Massive Transfusion Group
This group includes trauma patients who receive a massive transfusion, defined as the transfusion of at least 3 units of blood. Blood samples are collected at six specific timepoints following the administration of antibiotics to analyze plasma antibiotic concentrations. Existing clinical draws will be used whenever possible to minimize additional venipunctures, with a maximum of two dedicated research-only draws allowed if necessary. Data analysis will assess the impact of large blood transfusions on antibiotic pharmacokinetics over time, adjusting for factors such as kidney function.
- OTHER
-
Control Group
This group consists of trauma patients who receive minimal or no blood transfusions (up to 2 units of blood). Blood samples are also collected at six designated timepoints after antibiotic administration to measure plasma antibiotic concentrations. As with the massive transfusion group, clinical draws will be coordinated whenever possible to obtain research samples, with a maximum of two dedicated research-only draws if needed. Data analysis will compare antibiotic concentration trends in this group with those in the massive transfusion group to understand the effects of blood transfusion volume on antibiotic pharmacokinetics.
Sponsors & Collaborators
-
Congressionally Directed Medical Research Programs
collaborator FED -
The Metis Foundation
collaborator OTHER -
University of Colorado Health
collaborator OTHER -
Brooke Army Medical Center
lead FED
Principal Investigators
-
Julie A Rizzo, MD · Brooke Army Medical Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-30
- Primary Completion
- 2027-07-30
- Completion
- 2027-09-30
Countries
- United States
Study Locations
More Related Trials
-
Surgical Site Infection and Antibiotic Use Study
NCT04631185 ·Status: COMPLETED ·Phase: NA
-
Antibiotic Dosing in Geriatric Patients At the Emergency Department
NCT04436991 ·Status: RECRUITING
-
Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients
NCT04233996 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study on the Prophylactic Use of Antibiotics Within 72 Hours After Acute Burn Injury in Patients
NCT06221761 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer
NCT04637464 ·Status: COMPLETED ·Phase: NA
-
Vancomycin and Tobramycin Powder Use in Acute Open Fractures
NCT05849090 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion
NCT00435305 ·Status: TERMINATED
-
Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
NCT02149329 ·Status: COMPLETED ·Phase: PHASE4
-
Antibiotic Prophylaxis in Orthopaedic Traumatology
NCT00610987 ·Status: COMPLETED ·Phase: NA
-
Postoperative Antibiotics Following Primary and Secondary Breast Augmentation
NCT04834310 ·Status: WITHDRAWN ·Phase: PHASE4
-
LocalVancomycinPowderToPreventPeriprostheticJointInfection.
NCT05697965 ·Status: UNKNOWN ·Phase: PHASE2
-
Oral-only Antibiotics for Bone and Joint Infections in Children
NCT04563325 ·Status: COMPLETED ·Phase: PHASE4
-
Antibiotic Prophylaxis in Prosthetic Breast Reconstructions
NCT02012517 ·Status: UNKNOWN ·Phase: PHASE4
-
Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients
NCT01786161 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections
NCT02060513 ·Status: COMPLETED
-
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
NCT04648696 ·Status: TERMINATED ·Phase: PHASE4
-
Prophylactic Antibiotics on Urethral Catheter Withdrawal
NCT00126698 ·Status: COMPLETED ·Phase: PHASE4
-
Population Pharmacokinetics of Anti-infectives in Hospitalized Patients
NCT02998411 ·Status: RECRUITING
-
Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
NCT03078010 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
NCT06966284 ·Status: RECRUITING
-
Comparison of Solid Organ Transplant
NCT04055922 ·Status: UNKNOWN
-
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
NCT04876430 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF
NCT04358991 ·Status: COMPLETED
-
Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation
NCT00138112 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Prophylactic Antibiotics on Bloodstream Infections After Liberation From Extracorporeal Membrane Oxygenation
NCT05651464 ·Status: UNKNOWN ·Phase: NA